Octahydroindolo[2,3-a]quinolizines and 3,4-dihydro-beta-carbolines as new inhibitors of human platelet aggregation
Blaskó, G.; Blaskó, G.; Szántay, C.
Arzneimittel-Forschung 37(6): 667-669
1987
ISSN/ISBN: 0004-4172 PMID: 3311053 Document Number: 304022
Octahydroindolo[2,3-a]quinolizines and 3,4-dihydro-beta-carbolines proved to be powerful inhibitors of human platelet aggregation. They exhibited IC50 values two magnitudes lower than those of the commonly used cyclo-oxygenase inhibitors and no influence upon the routine parameters of blood coagulation was observed in vitro. Some of the compounds increased the vascular production of prostacyclin.
Document emailed within 1 workday
Related Documents
Nyby, M.D.; Sasaki, M.; Ideguchi, Y.; Wynne, H.E.; Hori, M.T.; Berger, M.E.; Golub, M.S.; Brickman, A.S.; Tuck, M.L. 1996: Platelet lipoxygenase inhibitors attenuate thrombin- and thromboxane mimetic-induced intracellular calcium mobilization and platelet aggregation Journal of Pharmacology and Experimental Therapeutics 278(2): 503-509Coudert, P.; Rubat, C.; Couquelet, J.; Tronche, P. 1990: Synthesis of 6-[(4-imidazol-1-yl)-phenyl]-4-phenyl 4,5-dihydro-2H-pyridazin-3-one: a potential blood platelet aggregation inhibitor Journal de Pharmacie de Belgique 45(3): 191-195
Gastpar, H. 1982: Platelet aggregation inhibitors and cancer metastasis Annales Chirurgiae et Gynaecologiae 71(3): 142-150
Panchenko, V.M.; Vladimirova, A.V.; Pastorova, V.E.; Sukhanova, S.A. 1980: Fibrinolysis and its inhibitors, and platelet aggregation in rheumatism Laboratornoe Delo 11: 671-675
Zannino, L.; Salvadori, G. 1979: Platelet aggregation inhibitors. their possible use in pediatric pathology Minerva Pediatrica 31(2): 153-169
Silveira, I.A.; Paulo, L.G.; Miranda, A.L.; Rocha, S.O.; Freitas, A.C.; Barreiro, E.J. 1991: Substituted pyrazolylhydrazones: a new class of platelet aggregation inhibitors Brazilian Journal of Medical and Biological Research 24(9): 947-951
Luo, H.W.; Hu, X.J.; Wang, N.; Ji, J. 1988: Platelet aggregation inhibitors from Salvia miltiorrhiza Bunge Yao Xue Xue Bao 23(11): 830-834
García Morillas, M.; Caracuel Ruiz, M.D.; Sánchez de la Cuesta, F. 1988: Interactions and undesirable side effects of platelet aggregation inhibitors Medicina Clinica 90(13): 553-555
David, J.L. 1987: Mode of action and clinical evaluation of platelet aggregation inhibitors Revue Medicale de Liege 42(10): 526-533
Espevik, T.; Figari, I.S.; Ranges, G.E.; Palladino, M.A. 1988: Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1 Journal of Immunology 140(7): 2312-2316
Ferreira, R. 1992: First Course of cardiovascular clinical pharmacology. II. Adjuvant therapy to thrombolysis. Anticoagulants and platelet aggregation inhibitors Revista Portuguesa de Cardiologia: Orgao Oficial da Sociedade Portuguesa de Cardiologia 11(3): 261-264
Arcari, M.; Aveta, R.; Brandt, A.; Cecchetelli, L.; Corsi, G.B.; Solinas, F. 1992: Synthesis and pharmacological evaluation of 2,3-dialkylindoles, "in vitro" inhibitors of thrombin-induced platelet aggregation Farmaco 47(4): 405-425
Dal Piaz, V.; Ciciani, G.; Giovannoni, M.P. 1997: Synthesis of 4,5-functionalized-2-methyl-6-(substituted aryl)-3 (2H)-pyridazinones: a new group of potent platelet aggregation inhibitors Farmaco 52(3): 173-178
Becq-Kayal, M-Christine. 2004: Management of a patient treated with anticoagulation agents or platelet aggregation inhibitors undergoing transurethral resection of the prostate (TRUP) Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 14(1 Suppl): 14-18
Zahavi, M.; Zahavi, J.; Kakkar, V.V. 1984: Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation Thrombosis and Haemostasis 52(2): 205-209
Iioka, H.; Hisanaga, H.; Moriyama, I.; Akasaki, M.; Nabuchi, K.; Katakami, Y.; Katoh, Y.; Ichijo, M. 1989: The study on the platelet aggregation inhibition activity of placental brush border (the mechanism of platelet aggregation inhibition) Nihon Sanka Fujinka Gakkai Zasshi 41(12): 1916-1920
Ambrus, J.L.; Ambrus, C.M.; Gastpar, H.; Williams, P. 1982: Study of platelet aggregation in vivo. IX. Effect of nafazatrom on in vivo platelet aggregation and spontaneous tumor metastasis Journal of Medicine 13(1-2): 35-47
Opartkiattikul, N.; Funahara, Y.; Fucharoen, S.; Talalak, P. 1992: Increase in spontaneous platelet aggregation in beta-thalassemia/hemoglobin E disease: a consequence of splenectomy Southeast Asian Journal of Tropical Medicine and Public Health 23(Suppl 2): 36-41
Zhu, L.; Shao, Y.D.; Wang, J.Y.; Lin, D.L.; Gu, C.L.; Li, Y.H.; Gu, J.G.; Dai, H.J.; Dong, J.C.; Xue, F. 1988: Effect of beta-phenyl lactic acid on platelet aggregation, thrombosis, and plasma cAMP content Zhongguo Yao Li Xue Bao 9(3): 249-251
Gandossi, E.; Lunven, C.; Gauffeny, C.; Roome, N.O.; Berry, C.N. 1998: Platelet aggregation induced in vitro by rabbit plasma clot-associated thrombin, and its inhibition by thrombin inhibitors Thrombosis and Haemostasis 80(5): 840-844